Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease
June 04, 2018 07:30 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, June 04, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa Hakko Kirin Co., Ltd....
Reata Selected to Present Early-Stage Programs at the BIO International Convention
June 01, 2018 16:15 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, June 01, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that Chief Development Officer, Keith Ward,...
Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome
May 31, 2018 16:15 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, May 31, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted...
Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study
May 25, 2018 03:30 ET
|
Reata Pharmaceuticals, Inc.
Interim Data Demonstrate Significant Improvement in Kidney Function in Both Diseases Conference Call With Management Scheduled Today, May 25, 2018 at 8:00am ET IRVING, Texas, May 25, 2018 (GLOBE...
Reata Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results and an Update on Development Programs
May 08, 2018 17:00 ET
|
Reata Pharmaceuticals, Inc.
CATALYST TRIAL IN CTD-PAH FINAL SAMPLE SIZE SET AT 200; TOP-LINE DATA EXPECTED IN THE FIRST HALF OF 2020 PHOENIX TRIAL INTERIM DATA FOR ADPKD AND IGA NEPHROPATHY COHORTS AT ERA-EDTA IN MAY; FULL DATA...
Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases
April 24, 2018 16:15 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, April 24, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced new preclinical data...
Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome
April 11, 2018 16:15 ET
|
Reata Pharmaceuticals, Inc.
Bardoxolone Treatment Produced Significant Increase in Kidney Function Maintained Through Week 36 Conference Call With Management Scheduled Thursday, April 12th at 8:30am ET IRVING, Texas, April ...
Reata to Present Preclinical Data on RTA 1701, a Novel RORγt Inverse Agonist, at Upcoming Immunology Conference
April 03, 2018 07:30 ET
|
Reata Pharmaceuticals, Inc.
Novel, Orally-Bioavailable Agent With Potent Activity in Cell-Based and Animal Models Non-Human Primate Proof-of-Concept for Suppression of IL-17A Achieved Phase 1 Initiation for RTA 1701...
Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan
March 29, 2018 16:15 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, March 29, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa...
Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial
March 22, 2018 07:30 ET
|
Reata Pharmaceuticals, Inc.
Significant Improvement in 6MWD in Patients With IPF and Sarcoidosis No Safety Signals Identified IRVING, Texas, March 22, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA)...